17.05.2010 • News

Air Products Nominates 3 To Airgas Board

Air Products and Chemicals nominated three heavyweight corporate executives to Airgas’ board on Thursday and wants shareholders to hold an annual meeting every January.

The action, which was expected, is the latest skirmish in the takeover battle between the two industrial gas companies. Air Products went hostile in its bid for Airgas last February, offering $60 per share in cash, or roughly $5.1 billion. Airgas was not available for comment.

Air Products wants to compel Airgas to hold its annual meeting every January. If passed by shareholders, that would force Airgas to hold another meeting as soon as January 2011. Since Airgas has a staggered board of nine directors, such a move would make it much easier for Air Products to gain a majority on the company's board. Airgas shareholders will consider the nominations and proposals at their meeting, on or before September 17.

Air Products nominated John Clancey, chairman emeritus of shipping company Maersk; Robert Lumpkins, chairman of fertilizer producer Mosaic; and Ted Miller, founder of wireless communication provider Crown Castle International. Air Products proposed that any board nominee put forward by Airgas who loses an election would be ineligible to serve on the board for the next three years.

Air Products is also seeking to have all bylaws adopted by Airgas' board after April 7, nullified. Air Products recently extended a tender deadline for Airgas shareholders until June 4. Some Airgas shareholders, as well as Air Products itself, have sued Airgas, hoping to force it to agree to the deal.

A Delaware judge declined to hold the trial quickly, instead opting for a fall trial after Airgas's shareholders meet.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.